封面
市場調查報告書
商品編碼
1566841

Ibuprofen市場:按類型、應用、分銷管道分類:2024-2033 年全球機會分析與產業預測

Ibuprofen Market By Type , By Application By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

Ibuprofen市場

2023年Ibuprofen市值為1億美元,預計2024年至2033年複合年成長率為7.9%,2033年達2.136億美元。

Ibuprofen是非類固醇消炎劑,因其能夠緩解疼痛、減輕發炎和退燒而廣受歡迎。它屬於鎮痛藥類別,用於緩解輕度至中度疼痛,如頭痛、肌肉痛、牙痛、月經痛和關節炎。此藥的作用機轉是抑制體內琴酒的產生,前列腺素是一種引起疼痛和發炎的化合物。

Ibuprofen在治療多種健康狀況方面的多功能性是市場的關鍵驅動力。此外,Ibuprofen作為非處方藥在某些國家的需求量很大,有助於自我治療並增加客戶的便利性。目前市場正出現一個新趨勢:藥品去石化。Ibuprofen的典型來源是原油。在最近的一項研究中,巴斯大學的研究人員發現了一種利用造紙工業產生的廢棄物開發藥物的方法。這項發現意味著製藥業向永續性邁出了重要一步。

儘管具有功效,長期使用Ibuprofen會引起嚴重的副作用,包括心血管風險、胃腸道併發症和腎臟損傷。這些因素導致許多人不服藥,從而限制了市場的成長。根據《英國醫學雜誌》發表的一項研究,Ibuprofen預計會使心臟麻痹的風險增加 31%。同樣,發表在《美國科學院院刊》上的一項研究發現,年輕健康男性服用高劑量的Ibuprofen會減少生殖激素的分泌,並導致補償性腺功能減退症的發生。

按部門審查

Ibuprofen市場分為類型、應用、分銷管道和區域。依類型分類,市場分為錠劑、膠囊、糖漿、注射等。依用途分為類風濕性關節炎/骨關節炎、癌症、疼痛/發燒/月經、發炎疾病、頭痛等。根據分銷管道,市場分為醫院藥房、零售藥房和網路藥房。從區域來看,分析涵蓋北美、歐洲、亞太地區和拉丁美洲/中東/非洲。

主要發現

按類型分類,錠劑細分市場將在 2023 年佔據市場佔有率。

從應用來看,類風濕性關節炎細分市場在 2023 年的收益最高。

從分銷管道來看,醫院藥房業務在2023年獲得了較高的市場佔有率。

按地區分類,預計到 2033 年,北美將主導市場。

該報告可以客製化。

  • 監管指引
  • 根據客戶興趣加入公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 擴大公司簡介列表
  • 歷史市場資料
  • 主要參與企業的詳細資料(Excel格式,包括位置、聯絡資訊、供應商/供應商網路等)

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 關鍵投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第 4 章Ibuprofen市場:按類型

  • 市場概況
  • 錠劑
  • 膠囊
  • 糖漿劑
  • 注射
  • 其他

第5章Ibuprofen市場:依應用分類

  • 市場概況
  • 類風濕性關節炎和骨關節炎
  • 癌症
  • 疼痛/發燒/月經
  • 發炎疾病
  • 頭痛
  • 其他

第6章Ibuprofen市場:按分銷管道

  • 市場概況
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章Ibuprofen市場:依地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國Ibuprofen市場
    • 加拿大Ibuprofen市場
    • 墨西哥Ibuprofen市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 德國Ibuprofen市場
    • 法國Ibuprofen市場
    • 英國Ibuprofen市場
    • 義大利Ibuprofen市場
    • 西班牙Ibuprofen市場
    • 其他歐洲Ibuprofen市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 日本Ibuprofen市場
    • 中國Ibuprofen市場
    • 澳洲Ibuprofen市場
    • 印度Ibuprofen市場
    • 韓國Ibuprofen市場
    • 其他亞太地區Ibuprofen市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • Ibuprofen市場
    • 沙烏地阿拉伯Ibuprofen市場
    • 南非Ibuprofen市場
    • 其他拉丁美洲/中東/非洲Ibuprofen市場

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位(2023年)

第9章 公司簡介

  • Pfizer Inc.
  • Abbott Laboratories
  • Solara Active Pharma Sciences Ltd
  • BASF SE
  • Biocause Inc
  • Shandong Xinhua Pharmaceutical Co Ltd
  • IOL Chemicals And Pharmaceutical Ltd
  • Hubei Biocause Pharmaceutical Co Ltd
  • Strides Pharma Science Ltd
  • Perrigo Company Plc
簡介目錄
Product Code: A65446

Ibuprofen Market

The ibuprofen market was valued at $100.0 million in 2023 and is projected to reach $213.6 million by 2033, growing at a CAGR of 7.9% from 2024 to 2033.

Ibuprofen is a nonsteroidal anti-inflammatory drug popular for its efficacy in alleviating pain, reducing inflammation, and lowering fever. It belongs to the analgesics class of medications which are used to ease mild to moderate pain, such as headaches, muscle aches, toothaches, menstrual cramps, and arthritis. The action mechanism of the medication involves inhibiting the production of prostaglandins inside the body, compounds that are the cause of pain and inflammation.

The versatility of ibuprofen in treating several health conditions is a key driver of the market. In addition, ibuprofen witnesses a high demand in several countries where it is accessible as over-the-counter medication, hence contributing to self-medication and elevating the convenience of customers. The market is currently witnessing an emerging trend of de-fossilization of pharmaceuticals. The typical source of formation of ibuprofen is from crude oils. Researchers at the University of Bath have recently discovered a method to develop the medication out of waste generated from the paper manufacturing industry. This discovery marks a significant step by the pharmaceuticals industry toward sustainability.

Despite its benefits, long-term usage of ibuprofen is known to cause severe side-effects such as cardiovascular risks, gastrointestinal complications, and kidney damage. These factors deter several individuals from the consumption of medication, hence restraining the market growth. According to a study posted by the British Medical Journal, ibuprofen is anticipated to elevate the risk of cardiac arrests by 31%. In a similar way, a study published in the Proceedings of the National Academy of Sciences states that high uptake of ibuprofen in young healthy men results in less production of reproductive hormones and occurrence of compensated hypogonadism disorder.

Segment Review

The ibuprofen market is segmented into type, application, distribution channel, and region. On the basis of type, the market is divided into tablet, capsule, syrup, injection, and others. As per application, it is classified into rheumatoid arthritis & osteoarthritis, cancer, pain/fever/dysmenorrhea, inflammatory diseases, headache, and others. Depending on distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of type, the tablet segment dominated the market share in 2023.

As per application, the rheumatoid arthritis segment generated the highest revenue in 2023.

Depending on distribution channel, the hospital pharmacies segment acquired a high market share in 2023.

Region wise, North America is expected to dominate the market by 2033.

Competition Analysis

The major players operating in the global ibuprofen market include Pfizer Inc., Abbott Laboratories Ltd., Solara Active Pharma Sciences Ltd., ?h?nd?ng ??nhu? ?h?rm???ut???l ??.Ltd, ??L ?h?m???l? and ?h?rm???ut???l L?m?t?d, ?ub?? ?????u?? ?h?rm???ut???l ??.Ltd, ?tr?d?? ?h?rm? ????n?? L?m?t?d (?h??un ?h?rm???ut???l? L?m?t?d), ??rr?g? ??m??n? ?l?, BASF SE, and Biocause Inc. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

  • Tablet
  • Capsule
  • Syrup
  • Injection
  • Others

By Application

  • Rheumatoid Arthritis and Osteoarthritis
  • Cancer
  • Pain/Fever/Dysmenorrhea
  • Inflammatory Diseases
  • Headache
  • Others

By Distribution Channel

  • Hospital pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Pfizer Inc.
    • Abbott Laboratories
    • Solara Active Pharma Sciences Ltd
    • BASF SE
    • Biocause Inc
    • Shandong Xinhua Pharmaceutical Co Ltd
    • IOL Chemicals and Pharmaceutical Ltd
    • Hubei Biocause Pharmaceutical Co Ltd
    • Strides Pharma Science Ltd
    • Perrigo Company Plc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: IBUPROFEN MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Tablet
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Capsule
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Syrup
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Injection
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country
  • 4.6. Others
    • 4.6.1. Key Market Trends, Growth Factors and Opportunities
    • 4.6.2. Market Size and Forecast, By Region
    • 4.6.3. Market Share Analysis, By Country

CHAPTER 5: IBUPROFEN MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Rheumatoid Arthritis And Osteoarthritis
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Cancer
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Pain/Fever/Dysmenorrhea
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Inflammatory Diseases
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country
  • 5.6. Headache
    • 5.6.1. Key Market Trends, Growth Factors and Opportunities
    • 5.6.2. Market Size and Forecast, By Region
    • 5.6.3. Market Share Analysis, By Country
  • 5.7. Others
    • 5.7.1. Key Market Trends, Growth Factors and Opportunities
    • 5.7.2. Market Size and Forecast, By Region
    • 5.7.3. Market Share Analysis, By Country

CHAPTER 6: IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Distribution Channel
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Retail Pharmacies
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Online Pharmacies
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: IBUPROFEN MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Type
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By Distribution Channel
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Ibuprofen Market
      • 7.2.6.1. Market Size and Forecast, By Type
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By Distribution Channel
    • 7.2.7. Canada Ibuprofen Market
      • 7.2.7.1. Market Size and Forecast, By Type
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By Distribution Channel
    • 7.2.8. Mexico Ibuprofen Market
      • 7.2.8.1. Market Size and Forecast, By Type
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Type
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By Distribution Channel
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Ibuprofen Market
      • 7.3.6.1. Market Size and Forecast, By Type
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By Distribution Channel
    • 7.3.7. France Ibuprofen Market
      • 7.3.7.1. Market Size and Forecast, By Type
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By Distribution Channel
    • 7.3.8. UK Ibuprofen Market
      • 7.3.8.1. Market Size and Forecast, By Type
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By Distribution Channel
    • 7.3.9. Italy Ibuprofen Market
      • 7.3.9.1. Market Size and Forecast, By Type
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By Distribution Channel
    • 7.3.10. Spain Ibuprofen Market
      • 7.3.10.1. Market Size and Forecast, By Type
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By Distribution Channel
    • 7.3.11. Rest of Europe Ibuprofen Market
      • 7.3.11.1. Market Size and Forecast, By Type
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Type
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By Distribution Channel
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Ibuprofen Market
      • 7.4.6.1. Market Size and Forecast, By Type
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By Distribution Channel
    • 7.4.7. China Ibuprofen Market
      • 7.4.7.1. Market Size and Forecast, By Type
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By Distribution Channel
    • 7.4.8. Australia Ibuprofen Market
      • 7.4.8.1. Market Size and Forecast, By Type
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By Distribution Channel
    • 7.4.9. India Ibuprofen Market
      • 7.4.9.1. Market Size and Forecast, By Type
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By Distribution Channel
    • 7.4.10. South Korea Ibuprofen Market
      • 7.4.10.1. Market Size and Forecast, By Type
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By Distribution Channel
    • 7.4.11. Rest of Asia-Pacific Ibuprofen Market
      • 7.4.11.1. Market Size and Forecast, By Type
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Type
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By Distribution Channel
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Ibuprofen Market
      • 7.5.6.1. Market Size and Forecast, By Type
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By Distribution Channel
    • 7.5.7. Saudi Arabia Ibuprofen Market
      • 7.5.7.1. Market Size and Forecast, By Type
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By Distribution Channel
    • 7.5.8. South Africa Ibuprofen Market
      • 7.5.8.1. Market Size and Forecast, By Type
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By Distribution Channel
    • 7.5.9. Rest of LAMEA Ibuprofen Market
      • 7.5.9.1. Market Size and Forecast, By Type
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Pfizer Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Abbott Laboratories
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Solara Active Pharma Sciences Ltd
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. BASF SE
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Biocause Inc
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Shandong Xinhua Pharmaceutical Co Ltd
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. IOL Chemicals And Pharmaceutical Ltd
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Hubei Biocause Pharmaceutical Co Ltd
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Strides Pharma Science Ltd
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Perrigo Company Plc
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments